Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $9.37 billion. The enterprise value is $2.60 billion.
Important Dates
The last earnings date was Friday, August 1, 2025, before market open.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 389.08 million shares outstanding. The number of shares has increased by 1.05% in one year.
| Current Share Class | 389.08M |
| Shares Outstanding | 389.08M |
| Shares Change (YoY) | +1.05% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 6.55% |
| Owned by Institutions (%) | 75.61% |
| Float | 363.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.07 |
| Forward PS | 4.84 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.93 |
| Quick Ratio | 3.55 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -233.79 |
Financial Efficiency
Return on equity (ROE) is -27.50% and return on invested capital (ROIC) is -17.69%.
| Return on Equity (ROE) | -27.50% |
| Return on Assets (ROA) | -14.78% |
| Return on Invested Capital (ROIC) | -17.69% |
| Return on Capital Employed (ROCE) | -31.36% |
| Revenue Per Employee | $530,690 |
| Profits Per Employee | -$500,517 |
| Employee Count | 5,800 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 16.52 |
Taxes
| Income Tax | -42.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.17% in the last 52 weeks. The beta is 1.83, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -69.17% |
| 50-Day Moving Average | 29.00 |
| 200-Day Moving Average | 32.33 |
| Relative Strength Index (RSI) | 33.74 |
| Average Volume (20 Days) | 8,913,899 |
Short Selling Information
The latest short interest is 62.83 million, so 16.15% of the outstanding shares have been sold short.
| Short Interest | 62.83M |
| Short Previous Month | 63.02M |
| Short % of Shares Out | 16.15% |
| Short % of Float | 17.29% |
| Short Ratio (days to cover) | 7.49 |
Income Statement
In the last 12 months, Moderna had revenue of $3.08 billion and -$2.90 billion in losses. Loss per share was -$7.53.
| Revenue | 3.08B |
| Gross Profit | -2.20B |
| Operating Income | -3.27B |
| Pretax Income | n/a |
| Net Income | -2.90B |
| EBITDA | -3.07B |
| EBIT | -3.27B |
| Loss Per Share | -$7.53 |
Full Income StatementBalance Sheet
The company has $5.13 billion in cash and $741.00 million in debt, giving a net cash position of $6.76 billion or $17.38 per share.
| Cash & Cash Equivalents | 5.13B |
| Total Debt | 741.00M |
| Net Cash | 6.76B |
| Net Cash Per Share | $17.38 |
| Equity (Book Value) | 9.40B |
| Book Value Per Share | 24.16 |
| Working Capital | 4.60B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.70 billion and capital expenditures -$793.00 million, giving a free cash flow of -$3.49 billion.
| Operating Cash Flow | -2.70B |
| Capital Expenditures | -793.00M |
| Free Cash Flow | -3.49B |
| FCF Per Share | -$8.97 |
Full Cash Flow StatementMargins
Gross margin is -71.44%, with operating and profit margins of -106.34% and -94.31%.
| Gross Margin | -71.44% |
| Operating Margin | -106.34% |
| Pretax Margin | -95.68% |
| Profit Margin | -94.31% |
| EBITDA Margin | -99.58% |
| EBIT Margin | -106.34% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.05% |
| Shareholder Yield | -1.05% |
| Earnings Yield | -30.99% |
| FCF Yield | -37.26% |
Dividend DetailsAnalyst Forecast
The average price target for Moderna is $43.50, which is 80.57% higher than the current price. The consensus rating is "Hold".
| Price Target | $43.50 |
| Price Target Difference | 80.57% |
| Analyst Consensus | Hold |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 18.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 5.27 and a Piotroski F-Score of 1.
| Altman Z-Score | 5.27 |
| Piotroski F-Score | 1 |
